Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with alpha-blocking agent doxazosin; versus placebo.

Abstract

The efficacy of doxazosin monotherapy in chronic non-bacterial prostatitis was investigated in terms of urinary symptom, pain and quality of life assessment versus placebo. A total of 60 men with chronic non-bacterial prostatitis were randomised to daily supplement of 4 mg doxazosin or a placebo, for 3 months. International Prostate Symptom Score (IPSS) questionnaire was self administered at the entry and at 3 months after the cessation of the treatment. In addition, patients were asked to complete 2-item questionnaire on pain related symptoms of chronic prostatitis. Quality of life was assessed with a single item included in IPSS. Three months after cessation of the treatment there was a significant difference between the overall mean IPSS, pain and quality of life scores of the two groups in favour of alpha-blocking agent use (p = 0.001, p < 0.001 and p < 0.001, respectively). In patients undergone doxazosin treatment; symptom, pain and quality of life status revealed 32.94 +/- 5.27%, 36.57 +/- 5.67% and 36.78 +/- 4.75% overall improvement, respectively. IPSS appeared to be a valuable tool in assessing treatment outcome of chronic non-bacterial prostatitis.

• Authors: Yalçin Evliyaoğlu, Refik Burgut
• Journal: International urology and nephrology (Int Urol Nephrol) Vol. 34 Issue 3 Pg. 351-6 ( 2002) ISSN: 0301-1623 [Print] Netherlands
• PMID: 12899226 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Adrenergic alpha-Antagonists
• Doxazosin

Topics

• Adrenergic alpha-Antagonists (therapeutic use)
• Adult
• Doxazosin (therapeutic use)
• Humans
• Male
• Middle Aged
• Pain (etiology, prevention & control)
• Pain Measurement
• Prospective Studies
• Prostatitis (complications, drug therapy, psychology)
• Quality of Life
• Treatment Outcome